From NASDAQ.:

Indiana legislators are considering funding clinical trials exploring the potential of psilocybin as a treatment for mental health disorders. Senate Bill 139, introduced by state Sen. Ed Charbonneau, would support studies on PTSD, anxiety, depression, bipolar disorder, chronic pain, and migraines. This bill is being filed as an emergency measure and could take effect immediately upon passage.

The bill doesn’t initially allocate any money, and researchers seeking funding would need to compare psilocybin’s effectiveness against existing treatments for specific conditions. Charbonneau has initiated discussions with Indiana University Health and Purdue University about psychedelics research. Adams, the U.S. Surgeon General under Donald Trump, is apparently open to exploring psilocybin despite his past skepticism towards medical marijuana.

While marijuana legalization continues to face hurdles in the Indiana legislature, psilocybin research may offer a new pathway for addressing mental health and medical concerns. By supporting research, Indiana could contribute valuable insights to the growing body of evidence on alternative treatments, potentially offering relief to those struggling with debilitating conditions.



Read more: GOP-Led Senate Bill In Indiana Targets PTSD, Depression With Psilocybin Research For Veterans, First Responders